Resource Center

Mar 3, 2021
  |  Video

Predicting the in vivo performance of BCS class II/IV drugs using a combined in vitro – in silico approach Case study: Albendazole and Albendazole sulfoxide

General Objective

Use of in vitro biorelevant experimentation in combination with in silico PBPK modeling to accurately predict the plasma concentrations of Abendazole and its main metabolite Albendazole sulfoxide after the oral administration of a tablet formulation in the fasted state.

By Maximo Pettarin, Edmund Kostewicz & Michael Bolger

Download Slides

Presented at SLP MIDD+ Virtual Conference March 3-4, 2021

Contact Us About This Video